Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 49

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 49
---
 
 applicable to the preferred shares;                                                      |

|  | the relative ranking and preferences of the preferred shares as to dividend rights and 
 rights if we liquidate, dissolve or wind up our affairs;                               |

|  | any limitations on the issuance of any class or series of preferred shares ranking senior                                                
 to or on a parity with the series of preferred shares as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; 
 and                                                                                                                                      |

|  | any other specific terms, preferences, rights or limitations of, or restrictions on, 
 the preferred shares.                                                                |

The issuance of preferred shares may or may not have a dilutive effect on the voting rights of shareholders owning common shares, depending on the rights and preferences set by the board of directors. Preferred shares may be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. However, except for such rights relating to the election of directors on a default in payment of dividends as may be attached to any series of the preferred shares by the board of directors or in connection with convertible preferred shares, the holders of preferred shares shall not be entitled, as such, to receive notice of, or to attend or vote at, any general meeting of our shareholders. Section 61 of the British Columbia Business Corporations Actprovides that the special rights attached to preferred shares may not be prejudiced or interfered with unless the shareholders holding such class of shares consent to such matter by a special resolution of such holders of preferred shares. Additionally, the issuance of preferred shares may have the effect of decreasing the market price of our common shares.

Series A-1 Convertible Preferred Shares

On October 30, 2024, we filed a notice of alteration to our Articles to amend our authorized share structure to amend the terms of a series of preferred shares, without par value, designated as “Series A-1 Convertible Preferred Shares” (the “Series A-1 Shares”). We are authorized to issue up to 500 Series A-1 Shares.

The Series A-1 Shares have a stated value of $10,000 per share and rank, with respect to redemption
payments, rights upon liquidation, dissolution or winding-up of the Company, or otherwise, senior in preference and priority to our common
shares, but equal to other series of preferred shares. The Company has the option to redeem the Series A-1 Shares, and upon conversion
or liquidation, holders are entitled to receive